(PHR) Phreesia - Ratings and Ratios

Phreesia, Inc. (NYSE:PHR) is a leading provider of SaaS-based healthcare solutions, offering a comprehensive platform that streamlines patient intake, appointment scheduling, and revenue cycle management. The company serves a diverse range of healthcare organizations, including single-specialty practices, multi-specialty groups, health systems, and pharmaceutical companies. Its platform integrates appointment scheduling, patient self-registration, insurance verification, and payment solutions, enhancing operational efficiency and patient engagement. Phreesias platform is accessible via multiple modalities, including mobile devices, self-service tablets, web-based dashboards, and on-site kiosks. Founded in 2005 and headquartered in Wilmington, Delaware, Phreesia operates in the United States and Canada.

From a technical perspective, PHR is currently trading at $25.23, with a 20-day SMA of $24.27 and a 50-day SMA of $25.46. The 200-day SMA stands at $24.14, indicating recent upward momentum. The Average True Range (ATR) of $1.30 suggests moderate volatility. The stocks average 20-day volume is approximately 455,550 shares.

On the fundamental side, Phreesia has a market capitalization of $1.408 billion. The forward P/E ratio is 90.91, reflecting high expectations for future earnings growth. The price-to-book (P/B) ratio is 5.32, and the price-to-sales (P/S) ratio is 3.36, indicating a premium valuation relative to its peers. However, the return on equity (RoE) is negative at -22.10%, highlighting ongoing profitability challenges.

3-Month Forecast:

Based on the technical and fundamental data, PHR is expected to experience continued volatility. The stock may face resistance near the $26-$27 range, given the recent crossing above the 50-day SMA. Support levels are likely to hold around $23-$24, aligned with the 200-day SMA. The ATR of $1.30 suggests daily price fluctuations of up to 5%. Fundamentally, the companys high P/S ratio and negative RoE may weigh on investor sentiment, while the forward P/E reflects optimism about future growth. Overall, PHR is likely to trade in a range-bound manner, with potential upside driven by strong revenue growth and improved profitability metrics.